Persistence and Adherence with Dementia Pharmacotherapy: Relevance of Patient, Provider, and System Factors
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
This paper provides a comprehensive review of studies examining adherence and (or) persistence with dementia pharmacotherapy during the past decade, including a summary of the key patient-, drug-, system-, and provider-level factors associated with these measures. Estimates of adherence and 1-year persistence to these drugs have ranged from 34% to 94% and 35% to 60%, respectively. Though many studies reported nonsignificant associations, there are data suggesting that patient age, sex, ethnoracial background, socioeconomic status, and region-specific reimbursement criteria, as well as the extent and quality of interactions among patients, caregivers, and providers, may influence persistence with pharmacotherapy. As many studies relied on administrative data, limited information was available regarding the relevance of patient's cognitive and functional status or the importance of caregiver involvement or assistive devices to adherence or persistence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H.-P., & van den Bussche, H. (2005) · BMJ · doi:10.1136/bmj.331.7512.321 · Cited by 522
Rolinski, M., Fox, C., Maidment, I., & McShane, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006504.pub2 · Cited by 418
Doody, R. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.427 · Cited by 362
Medication Adherence in Older Adults With Cognitive Impairment: A Systematic Evidence-Based Review
Campbell, N. L., Boustani, M. A., Skopelja, E. N., Gao, S., Unverzagt, F. W., & Murray, M. D. (2012) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2012.04.004 · Cited by 206
Hogan, D. B., Bailey, P., Black, S., Carswell, A., Chertkow, H., Clarke, B., Cohen, C., Fisk, J. D., Forbes, D., Man-Son-Hing, M., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.081103 · Cited by 167
Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease
Herrmann, N., & Gauthier, S. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.070804 · Cited by 140
Self-citation
Cited by
Deardorff, W. J., & Grossberg, G. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86463 · Cited by 125
“The estimated rate of adherence to AD therapies is in the range of 34%–94%, with a discontinuation rate for ChEIs ranging from 40% to 65% after 1 year and up to 90% after 2–3 years.(61,62) In a claims analysis of 3,091 patients with AD new to oral AD therapy, only 58% were found to be adherent to oral therapy and 40%…”
on behalf of the Registry of Dementias of Girona Study Group (ReDeGi Study Group), Calvó-Perxas, L., Turró-Garriga, O., Vilalta-Franch, J., Lozano-Gallego, M., de Eugenio, R., Márquez, F., Carmona, O., Gich, J., Manzano, A., et al. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0446-x · Cited by 30
Kröger, E., Tatar, O., Vedel, I., Giguère, A. M. C., Voyer, P., Guillaumie, L., Grégoire, J.-P., & Guénette, L. (2017) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-017-0487-6 · Cited by 23
Muñoz-Contreras, M. C., Segarra, I., López-Román, F. J., Galera, R. N., & Cerdá, B. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.987936 · Cited by 25
Metadata
- Authors
- Maxwell, C. J., Stock, K., Seitz, D., & Herrmann, N.
- Venue
- The Canadian Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2014-12
- Volume
- 59
- Issue
- 12
- Pages
- 624-631
- ISSN
- 0706-7437 (ISSN-L)
- 1497-0015
- OpenAlex
- W320179842
- Cited by
- 63
- References
- 15
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Persistence and Adherence with Dementia Pharmacotherapy: Relevance of Patient, Provider, and System Factors. https://app.cochat.ai/papers/10.1177/070674371405901203
- The paper
- Maxwell, C. J., Stock, K., Seitz, D., & Herrmann, N. (2014). Persistence and Adherence with Dementia Pharmacotherapy: Relevance of Patient, Provider, and System Factors. The Canadian Journal of Psychiatry. https://doi.org/10.1177/070674371405901203
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.